Mebeverine
- Generic Name
- Mebeverine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H35NO5
- CAS Number
- 3625-06-7
- Unique Ingredient Identifier
- 7F80CC3NNV
- Background
Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.
- Indication
治疗由肠易激综合症（IBS）引起的腹痛痉挛，肠功能紊乱和肠部不适，治疗由于器质性疾病继发引起的肠痉挛。
- Associated Conditions
- Abdominal Pain, Abdominal Spasms, Abnormal Bowel Movement Such as Constipation, Diarrhea, Abdominal Pain, Irritable Bowel Syndrome (IBS), Bowel discomfort
- Associated Therapies
- -
Ebastine Versus Mebeverine in IBS Patients
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Guy Boeckxstaens
- Target Recruit Count
- 200
- Registration Number
- NCT05815602
- Locations
- 🇧🇪
UZLeuven, Leuven, Vlaams-Brabant, Belgium
🇧🇪GZA, Antwerpen, Belgium
🇧🇪AZ St-Maarten, Mechelen, Antwerpen, Belgium
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
- Conditions
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 465
- Registration Number
- NCT05175131
- Locations
- 🇷🇺
Null Research Facilities, Moscow, Russian Federation
Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-01-03
- Last Posted Date
- 2020-01-03
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 60
- Registration Number
- NCT04217733
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2019-06-06
- Lead Sponsor
- Abbott
- Target Recruit Count
- 220
- Registration Number
- NCT02260154
- Locations
- 🇷🇺
Research Facility ID ORG-001038, Izhevsk, Russian Federation
🇷🇺State Budget Institution " Irkutsk State Medical Academy of postgraduate education", Irkutsk, Russian Federation
🇷🇺Research Facility ID ORG-001035, Chita, Russian Federation
Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Hazel Everitt
- Target Recruit Count
- 135
- Registration Number
- NCT00934973
- Locations
- 🇬🇧
University of Southampton, Southampton, Hampshire, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.